Survivorship care plan outcomes for primary care physicians, cancer survivors, and systems: a scoping review.

J Cancer Surviv

Department of Family & Community Medicine, University of Arizona Cancer Center, University of Arizona, 1450 N. Cherry Ave, Tucson, AZ, 85719, USA.

Published: June 2018

Purpose: With the focus on survivorship care-coordination between oncology and primary care providers (PCPs), there is a need to assess the research regarding the use of survivorship care plans (SCPs) and determine emerging research areas. We sought to find out how primary care physicians have been involved in the use of SCPs and determine SCP's effectiveness in improving care for cancer survivors. In this scoping review, we aimed to identify gaps in the current research and reveal opportunities for further research.

Methods: We followed the methodology for scoping studies which consists of identifying the research question, locating relevant studies, selecting studies, charting the data, and collating, summarizing, and reporting the results.

Results: Out of 5375 original articles identified in the literature search, 25 met the inclusion/exclusion criteria. Eight articles examined PCP-only related outcomes, eight examined survivor-only related outcomes, eight examined mixed outcomes between both groups, and one examined system-based outcomes. Findings highlighted several areas where SCPs may provide benefits, including increased confidence among PCPs in managing the care of survivors and increased quality of life and well-being for survivors. This research also highlighted the need for careful consideration of SCP mode of delivery and content in order to maximize their utility to patients and providers.

Conclusions: Based on the findings of this review, SCPs may benefit providers and health care systems, but the benefits to patients remain unclear. Further research on the potential benefits of SCPs to particular patient populations is warranted.

Implications For Cancer Survivors: SCPs appear to be beneficial to PCPs in improving overall quality of care. However, more work needs to be done to understand the direct impact on cancer survivors.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-017-0673-5DOI Listing

Publication Analysis

Top Keywords

cancer survivors
16
primary care
12
survivorship care
8
care
8
care physicians
8
scoping review
8
scps determine
8
outcomes examined
8
survivors
6
scps
6

Similar Publications

Background: The aim of the SURECAN trial is to evaluate a person-centred intervention, based on Acceptance and Commitment Therapy (ACT Plus ( +)), for people who have completed treatment for cancer with curative intent, but are experiencing poor quality of life. We present the statistical analysis plan for assessing the effectiveness and cost-effectiveness of the intervention in improving quality of life 1 year post randomisation.

Methods And Design: SURECAN is a multi-centre, pragmatic, two-arm, partially clustered randomised controlled superiority trial comparing the effectiveness of ACT + added to usual care with usual aftercare.

View Article and Find Full Text PDF

Ongoing Symptoms and Concerns Experienced by Low-Risk Breast Cancer Survivors Following Active Treatment.

Ann Surg Oncol

January 2025

Department of Surgery, School of Medicine and Public Health, Wisconsin Surgical Outcomes Research Program, University of Wisconsin, Madison, WI, USA.

Introduction: Little is known about the symptom burden of breast cancer survivors with early-stage disease. Many studies have focused on symptoms of patients who are undergoing or recently completed systemic therapy. However, with the increased use of Oncotype DX, the proportion of early-stage hormone receptor-positive patients who undergo chemotherapy has declined, making existing studies of the symptom experience less useful for these patients.

View Article and Find Full Text PDF

Effectiveness of tailored interventions on quality of life in cancer survivors: A systematic review.

Patient Educ Couns

January 2025

College of Nursing, Seoul National University, Seoul, South Korea; Center for World-leading Human-care Nurse Leaders for the Future by Brain Korea 21 (BK 21) four project, College of Nursing, Seoul National University, Seoul, South Korea.

Objectives: This systematic review aimed to identify effective components and assess the statistical, practical, and clinical significance of tailored interventions for enhancing cancer survivors' quality of life.

Methods: Twenty-four clinical trials were selected based on search results from five databases. Study quality was assessed using the Cochrane Risk of Bias Tool 2.

View Article and Find Full Text PDF

Mucinous ovarian carcinoma: Impact of ovarian stimulation, hormonal contraception, and hormone replacement therapy.

Eur J Obstet Gynecol Reprod Biol

January 2025

Département de chirurgie, centre Léon Bérard, Lyon, France; INSERM U1290 RESHAPE, France; Hôpital Femme Mère Enfant, Bron, France. Electronic address:

Unlike high-grade serous carcinoma (HGSC), which mainly affects postmenopausal women, mucinous ovarian carcinoma (MOC) affects younger patients, with a median age at diagnosis of 53 years, and is rare among premenopausal women. After they receive anticancer treatment, these women encounter specific issues involving fertility preservation (FP) and/or pregnancy, which potentially require assisted reproductive technology (ART) as well as the prescription of hormonal contraception (HC) or hormone replacement therapy (HRT). We reviewed the available literature in PubMed/Medline concerning the risks of the development of ovarian cancer (OC), including MOC, associated with ART, HC and HRT, and literature on the impact of ovarian stimulation in the context of FP and/or ART, HC and HRT in women previously treated for OC, including MOC.

View Article and Find Full Text PDF

Purpose: This meta-analysis aims to estimate the global prevalence of severe, moderate, overall malnutrition and moderating factors of malnutrition in colorectal cancer (CRC) survivors.

Methods: A comprehensive search was conducted in Embase, CINAHL, Medline-OVID, PubMed, Scopus, and Web of Science from inception to February 8, 2024, without language, region, or publication date restrictions. A generalized linear mixed model and random-effects model were used to examine the pooled prevalence, and moderator analyses were implemented to investigate variations in the pooled prevalence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!